268 related articles for article (PubMed ID: 30373278)
21. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever.
Cross RW; Woolsey C; Prasad AN; Borisevich V; Agans KN; Deer DJ; Geisbert JB; Dobias NS; Fenton KA; Geisbert TW
Cell Rep; 2022 Jul; 40(3):111094. PubMed ID: 35858566
[TBL] [Abstract][Full Text] [Related]
22. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.
Safronetz D; Rosenke K; Westover JB; Martellaro C; Okumura A; Furuta Y; Geisbert J; Saturday G; Komeno T; Geisbert TW; Feldmann H; Gowen BB
Sci Rep; 2015 Oct; 5():14775. PubMed ID: 26456301
[TBL] [Abstract][Full Text] [Related]
23. In-silico identification of the vaccine candidate epitopes against the Lassa virus hemorrhagic fever.
Baral P; Pavadai E; Gerstman BS; Chapagain PP
Sci Rep; 2020 May; 10(1):7667. PubMed ID: 32376973
[TBL] [Abstract][Full Text] [Related]
24. CEPI: Driving Progress Toward Epidemic Preparedness and Response.
Gouglas D; Christodoulou M; Plotkin SA; Hatchett R
Epidemiol Rev; 2019 Jan; 41(1):28-33. PubMed ID: 31673694
[TBL] [Abstract][Full Text] [Related]
25. Differential pathogenesis of closely related 2018 Nigerian outbreak clade III Lassa virus isolates.
Stein DR; Warner BM; Audet J; Soule G; Siragam V; Sroga P; Griffin BD; Leung A; Grolla A; Tierney K; Albietz A; Kobasa D; Musa AS; Ahmad A; Akinpelu AM; Mba N; Rosenke R; Scott DP; Saturday G; Ihekweazu C; Safronetz D
PLoS Pathog; 2021 Oct; 17(10):e1009966. PubMed ID: 34634087
[TBL] [Abstract][Full Text] [Related]
26. Routine and pulse vaccination for Lassa virus could reduce high levels of endemic disease: A mathematical modelling study.
Davies J; Lokuge K; Glass K
Vaccine; 2019 Jun; 37(26):3451-3456. PubMed ID: 31088745
[TBL] [Abstract][Full Text] [Related]
27. Lethal Infection of Lassa Virus Isolated from a Human Clinical Sample in Outbred Guinea Pigs without Adaptation.
Maruyama J; Manning JT; Mateer EJ; Sattler R; Bukreyeva N; Huang C; Paessler S
mSphere; 2019 Sep; 4(5):. PubMed ID: 31554720
[TBL] [Abstract][Full Text] [Related]
28. Vaccine platforms for the prevention of Lassa fever.
Purushotham J; Lambe T; Gilbert SC
Immunol Lett; 2019 Nov; 215():1-11. PubMed ID: 31026485
[TBL] [Abstract][Full Text] [Related]
29. Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development.
Hallam HJ; Hallam S; Rodriguez SE; Barrett ADT; Beasley DWC; Chua A; Ksiazek TG; Milligan GN; Sathiyamoorthy V; Reece LM
NPJ Vaccines; 2018; 3():11. PubMed ID: 29581897
[TBL] [Abstract][Full Text] [Related]
30. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.
Robinson JE; Hastie KM; Cross RW; Yenni RE; Elliott DH; Rouelle JA; Kannadka CB; Smira AA; Garry CE; Bradley BT; Yu H; Shaffer JG; Boisen ML; Hartnett JN; Zandonatti MA; Rowland MM; Heinrich ML; Martínez-Sobrido L; Cheng B; de la Torre JC; Andersen KG; Goba A; Momoh M; Fullah M; Gbakie M; Kanneh L; Koroma VJ; Fonnie R; Jalloh SC; Kargbo B; Vandi MA; Gbetuwa M; Ikponmwosa O; Asogun DA; Okokhere PO; Follarin OA; Schieffelin JS; Pitts KR; Geisbert JB; Kulakoski PC; Wilson RB; Happi CT; Sabeti PC; Gevao SM; Khan SH; Grant DS; Geisbert TW; Saphire EO; Branco LM; Garry RF
Nat Commun; 2016 May; 7():11544. PubMed ID: 27161536
[TBL] [Abstract][Full Text] [Related]
31. Immunobiology of Ebola and Lassa virus infections.
Prescott JB; Marzi A; Safronetz D; Robertson SJ; Feldmann H; Best SM
Nat Rev Immunol; 2017 Mar; 17(3):195-207. PubMed ID: 28111475
[TBL] [Abstract][Full Text] [Related]
32. PROSPECTS OF LASSA FEVER CANDIDATE VACCINES.
Isaac AB; Karolina W; Temitope AA; Anuska R; Joanne E; Deborah A; Bianca OC; Filip T; Zofia P; Oluwasegun OI; Oluwaferanmi O; Grace BT
Afr J Infect Dis; 2022; 16(2 Suppl):46-58. PubMed ID: 36124324
[TBL] [Abstract][Full Text] [Related]
33. Lassa Virus Reverse Genetics.
Martínez-Sobrido L; Paessler S; de la Torre JC
Methods Mol Biol; 2017; 1602():185-204. PubMed ID: 28508222
[TBL] [Abstract][Full Text] [Related]
34. Construction and Immunological Evaluation of an Adenoviral Vector-Based Vaccine Candidate for Lassa Fever.
Wang M; Li R; Li Y; Yu C; Chi X; Wu S; Liu S; Xu J; Chen W
Viruses; 2021 Mar; 13(3):. PubMed ID: 33804206
[TBL] [Abstract][Full Text] [Related]
35. Transcriptome analysis of human peripheral blood mononuclear cells exposed to Lassa virus and to the attenuated Mopeia/Lassa reassortant 29 (ML29), a vaccine candidate.
Zapata JC; Carrion R; Patterson JL; Crasta O; Zhang Y; Mani S; Jett M; Poonia B; Djavani M; White DM; Lukashevich IS; Salvato MS
PLoS Negl Trop Dis; 2013; 7(9):e2406. PubMed ID: 24069471
[TBL] [Abstract][Full Text] [Related]
36. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot.
Mateo M; Reynard S; Carnec X; Journeaux A; Baillet N; Schaeffer J; Picard C; Legras-Lachuer C; Allan R; Perthame E; Hillion KH; Pietrosemoli N; Dillies MA; Barrot L; Vallve A; Barron S; Fellmann L; Gaillard JC; Armengaud J; Carbonnelle C; Raoul H; Tangy F; Baize S
Sci Transl Med; 2019 Oct; 11(512):. PubMed ID: 31578242
[TBL] [Abstract][Full Text] [Related]
37. Passive Transfer of Animal-Derived Polyclonal Hyperimmune Antibodies Provides Protection of Mice from Lethal Lassa Virus Infection.
Oestereich L; Müller-Kräuter H; Pallasch E; Strecker T
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515124
[TBL] [Abstract][Full Text] [Related]
38. Axl Can Serve as Entry Factor for Lassa Virus Depending on the Functional Glycosylation of Dystroglycan.
Fedeli C; Torriani G; Galan-Navarro C; Moraz ML; Moreno H; Gerold G; Kunz S
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237830
[TBL] [Abstract][Full Text] [Related]
39. HLA-C-restricted viral epitopes are associated with an escape mechanism from KIR2DL2
Wauquier N; Petitdemange C; Tarantino N; Maucourant C; Coomber M; Lungay V; Bangura J; Debré P; Vieillard V
EBioMedicine; 2019 Feb; 40():605-613. PubMed ID: 30711514
[TBL] [Abstract][Full Text] [Related]
40. ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge.
Fischer RJ; Purushotham JN; van Doremalen N; Sebastian S; Meade-White K; Cordova K; Letko M; Jeremiah Matson M; Feldmann F; Haddock E; LaCasse R; Saturday G; Lambe T; Gilbert SC; Munster VJ
NPJ Vaccines; 2021 Mar; 6(1):32. PubMed ID: 33654106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
